8 Aug 2019 - The Global In Situ
Hybridization Market is subject
to witness a substantial growth due to the rising demand for molecular
diagnostic tools and increasing adoption of ISH technology. Growing prevalence
of chronic diseases along with rising demand for rapid diagnostic techniques
are anticipated to foster market growth over the forecast period. Globally, the
market is predicted to grow at CAGR of 7.8% in the forecast period, providing
numerous opportunities for market players to invest for research and
development in the In Situ hybridization market.
The
conventional methodologies such as clinical trials were influenced by factors
such as the growing competition, rising prices of medicines and strict
governmental laws to limit adverse effects on the environment. With advent of
the In Situ hybridization, such factors are significantly diminished due
numerous advantages provided with the use of the In Situ hybridization.
Benefits associated with adoption of In Situ hybridization are superior
performance, successful trials, reliability and short timeframes for execution
of clinical trial, and cost-effectiveness.
Rising
prevalence of cancer-related diseases is expected to boost market demand for In
Situ hybridization over the upcoming years. In addition, increasing adoption of
DNA probe-based diagnostics for identification of diseases that are caused by
pathogen or bacteria is estimated to drive market growth. Rise in the number of
incidence related to genetic disorders, solid tumors, leukemia, autism, and
other syndromes are predicted to stimulate market demand for In Situ
hybridization over the forecast period.
The
market is broadly categorized into major four segments based on the product
type such as instruments, kits & probes, software and services. The
instruments is considered as one of the fastest growing segment in the In Situ
hybridization market with substantial revenue generation in the last few years.
Growing popularity of the instruments segment among healthcare professionals is
attributed to the rise in the demand from diagnostic and research laboratories.
The kits & probes segment has also witnessed substantial growth owing to
the growing incidence of target disorders such as cancer.
The
market is divided by region as North America, Europe, Asia-Pacific, Latin
America and Africa. North America has shown major growth in recent years owing
to the rise in the implementation of latest technologies in pharmaceuticals
& medicine sector, higher penetration rates, increase in the demand for
disposable devices from healthcare professionals, and existence of
well-established infrastructure.
Asia-Pacific
region is predicted to hold major market share in the In Situ hybridization
market with massive growth in forecast period. Countries such as India, China
and Singapore are leading the Asia-Pacific market with increasing healthcare
expenditure, growing prevalence of cancer related diseases, presence of
high-unmet patient needs, and significant investment by leading industry
players considering potential growth opportunities in the region.
The
key players in the In Situ hybridization market are Thermo Fisher Scientific
Co., Leica BiosystemsNussloch GmbH, BIOVIEW, Inc., Agilent Technologies, Inc.,
Merck KGaA, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., NeoGenomics
Laboratories, Inc., Advanced Cell Diagnostics, Inc., and Oxford Gene Technology
Co.
Market Segment:
Market Leaders
•
Leica Biosystems Nussloch GmbH
•
Thermo Fisher Scientific
•
F. Hoffmann-La Roche AG
•
Abbott Laboratories
•
Agilent Technologies
•
PerkinElmer
•
Qiagen / Exiqon A/S
•
Merck KGaA
•
BioGenex Laboratories
•
BioTechne / Advanced Cell Diagnostics (ACD)
Key Topics
•
In Situ Hybridization
•
Molecular Diagnostics
•
Cervical Cancer Stain
•
Fish Steps Reduction
•
Fluorescence In Situ Hybridization (FISH)
•
In Situ Hybridization (ISH)
•
FISH Probe Kit
Comments
Post a Comment